These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30507711)

  • 1. Relationship between sex hormone binding globulin and blood coagulation in women on postmenopausal hormone treatment.
    Eilertsen AL; Dahm AEA; Høibraaten E; Lofthus CM; Mowinckel MC; Sandset PM
    Blood Coagul Fibrinolysis; 2019 Jan; 30(1):17-23. PubMed ID: 30507711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjugated estrogen/progestagen versus tibolone hormone replacement therapy in postmenopausal women: Effects on carbohydrate metabolism and serum sex hormone-binding globulin.
    Odmark IS; Carlström K; Jonsson B; Jonasson AF
    Maturitas; 2006 Jan; 53(1):89-96. PubMed ID: 15964160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
    Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
    Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
    Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
    Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex hormone-binding globulin levels are not causally related to venous thrombosis risk in women not using hormonal contraceptives.
    Stegeman BH; Helmerhorst FM; Vos HL; Rosendaal FR; Van Hylckama Vlieg A
    J Thromb Haemost; 2012 Oct; 10(10):2061-7. PubMed ID: 22882730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives.
    Raps M; Helmerhorst F; Fleischer K; Thomassen S; Rosendaal F; Rosing J; Ballieux B; VAN Vliet H
    J Thromb Haemost; 2012 Jun; 10(6):992-7. PubMed ID: 22469296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone therapy and raloxifene reduce the coagulation inhibitor potential.
    Andresen MS; Eilertsen AL; Abildgaard U; Sandset PM
    Blood Coagul Fibrinolysis; 2007 Jul; 18(5):455-60. PubMed ID: 17581320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women.
    Ziaei S; Moghasemi M; Faghihzadeh S
    Climacteric; 2010 Apr; 13(2):147-56. PubMed ID: 19731119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
    Post MS; Christella M; Thomassen LG; van der Mooren MJ; van Baal WM; Rosing J; Kenemans P; Stehouwer CD
    Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1116-21. PubMed ID: 12730085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.
    Eilertsen AL; Sandvik L; Mowinckel MC; Andersen TO; Qvigstad E; Sandset PM
    Thromb Res; 2007; 120(3):371-9. PubMed ID: 17156824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex hormone-binding globulin and antithrombin III activity in women with oral ultra-low-dose estradiol.
    Matsui S; Yasui T; Kasai K; Keyama K; Yoshida K; Kato T; Uemura H; Kuwahara A; Matsuzaki T; Irahara M
    J Obstet Gynaecol; 2017 Jul; 37(5):627-632. PubMed ID: 28317410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Serum Sex Hormones with Hemostatic Factors in Women On and Off Hormone Therapy: The Multiethnic Study of Atherosclerosis.
    Williams MS; Cushman M; Ouyang P; Heckbert SR; Kalyani RR; Vaidya D
    J Womens Health (Larchmt); 2016 Feb; 25(2):166-72. PubMed ID: 26700933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women.
    Dahm AE; Eilertsen AL; Goeman J; Olstad OK; Ovstebø R; Kierulf P; Mowinckel MC; Skretting G; Sandset PM
    Thromb Res; 2012 Jul; 130(1):45-51. PubMed ID: 22217510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-sectional association of coffee and caffeine consumption with sex hormone-binding globulin in healthy nondiabetic women.
    Pihan-Le Bars F; Gusto G; Boutron-Ruault MC; Fagherazzi G; Bonnet F
    Clin Endocrinol (Oxf); 2017 Nov; 87(5):475-483. PubMed ID: 28664630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation.
    Eilertsen AL; Qvigstad E; Andersen TO; Sandvik L; Sandset PM
    Maturitas; 2006 Oct; 55(3):278-87. PubMed ID: 16713143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitor.
    Khialani D; Vasan S; Cushman M; Dahm AEA; Sandset PM; Rossouw J; van Hylckama Vlieg A
    J Thromb Haemost; 2021 Jul; 19(7):1729-1737. PubMed ID: 33774921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.
    Lasco A; Gaudio A; Morini E; Morabito N; Nicita-Mauro C; Catalano A; Denuzzo G; Sansotta C; Xourafa A; Macrì I; Frisina N
    Menopause; 2006; 13(5):787-92. PubMed ID: 16912660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers.
    Eilertsen AL; Sandvik L; Steinsvik B; Sandset PM
    J Thromb Haemost; 2008 Jun; 6(6):928-34. PubMed ID: 18394014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between endogenous estrogen, sex hormone-binding globulin, and bone loss in female residents of a rural Japanese community: the Taiji Study.
    Yoshimura N; Kasamatsu T; Sakata K; Hashimoto T; Cooper C
    J Bone Miner Metab; 2002; 20(5):303-10. PubMed ID: 12203037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.